A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Clinical trial NCT05565378 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05565378
Sponsor: GlaxoSmithKline
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Cancer, Non-Small Cell

Start date: 2022-10-14
Primary completion: 2026-11-09
Enrollment: 351

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.